{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:32:19Z","timestamp":1794472339025,"version":"4.9.1"},"reference-count":14,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>We assessed insulin sensitivity and \u03b2-cell function in adults with obesity\/overweight, without diabetes, treated with tirzepatide for 72 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI \u226527 kg\/m2 and either prediabetes or normoglycemia at baseline. Model-derived parameters of \u03b2-cell function and insulin sensitivity were assessed from oral glucose tolerance tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and \u03b2-cell function measures overall and in participants with prediabetes or normoglycemia. In multivariate regression models, improvements in insulin sensitivity were associated mostly with weight reduction and partly with tirzepatide treatment, whereas enhancement in \u03b2-cell function was mostly associated with tirzepatide treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In adults with obesity\/overweight without type 2 diabetes, tirzepatide treatment was associated with improved \u03b2-cell function and insulin sensitivity, partly independent of weight reduction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-0763","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:21:09Z","timestamp":1753204869000},"page":"1622-1627","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":17,"title":["Tirzepatide Treatment and Associated Changes in \u03b2-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-5591","authenticated-orcid":false,"given":"Andrea","family":"Mari","sequence":"first","affiliation":[{"name":"CNR Institute of Neuroscience 1 , Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Stefanski","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 2 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"van Raalte","sequence":"additional","affiliation":[{"name":"Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center 3 , Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosu","family":"Ma","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 2 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"LaBell","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 2 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludi","family":"Fan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 2 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 2 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 2 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathijs C.","family":"Bunck","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 2 , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[{"name":"CNR Institute of Clinical Physiology 4 , Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2026061714341815300_B1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061714341815300_B2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061714341815300_B3","doi-asserted-by":"crossref","first-page":"bvad056","DOI":"10.1210\/jendso\/bvad056","article-title":"Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1)","volume":"7","author":"Lee","year":"2023","journal-title":"J Endocr Soc"},{"key":"2026061714341815300_B4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061714341815300_B5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2026061714341815300_B6","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1152\/ajpendo.00093.2002","article-title":"Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects","volume":"283","author":"Mari","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026061714341815300_B7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061714341815300_B8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"2026061714341815300_B9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/diacare.24.3.539","article-title":"A model-based method for assessing insulin sensitivity from the oral glucose tolerance test","volume":"24","author":"Mari","year":"2001","journal-title":"Diabetes Care"},{"key":"2026061714341815300_B10","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1210\/clinem\/dgae319","article-title":"Effects of tirzepatide vs semaglutide on \u03b2-cell function, insulin sensitivity, and glucose control during a meal test","volume":"109","author":"Mather","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061714341815300_B11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2026061714341815300_B12","first-page":"S517","article-title":"A long-acting glucose dependent insulinotropic polypeptide receptor agonist improves insulin sensitivity and beta cell function in subjects with type 2 diabetes (abstract LBA 17)","volume":"67","author":"Heise","year":"2024","journal-title":"Diabetologia"},{"key":"2026061714341815300_B13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/dom.16159","article-title":"Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: an exploratory analysis","volume":"27","author":"Mather","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026061714341815300_B14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/9\/1622\/837530\/dc250763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/9\/1622\/837530\/dc250763.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:34:26Z","timestamp":1781721266000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/9\/1622\/163002\/Tirzepatide-Treatment-and-Associated-Changes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":14,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-0763","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}